A Study of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors
- Registration Number
- NCT06117566
- Lead Sponsor
- Shanghai Jiatan Pharmatech Co., Ltd
- Brief Summary
The goal of this clinical trial is to evaluate the safety and preliminary efficacy of WX390 combined with Toripalimab in patients with advanced solid tumors. The main questions it aims to answer are:
* the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of WX390;
* safety and preliminary in combined therapy. Participants will be treated with WX390 orally and Toripalimab intravenously, and follow the efficacy and safety evaluation according to the protocol.
- Detailed Description
This study will be an open-label, multicenter phase Ib/IIa clinical trial. After being informed about the study and potential risks, all patients giving written informed consent will undergo a 4-week screening period to determine eligibility for study entry. And then patents will be administered for 8 cycles treatment and 8 weeks safety follow up after the last dose of treatment. The efficacy and safety measures will be conducted and collected every cycle.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 100
- ≥18 years of age
- Histological or cytological confirmed advanced solid tumor, standard regimen failed or no standard regimen available
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- Life expectancy of more than 3 months
- At least one measurable lesion according to RECIST 1.1
- Adequate organ function，
- Signed and dated informed consent
- Anti-cancer therapy within 30 days prior to the initiation of investigational treatment
- Major surgery within 30 days prior to the initiation of study treatment
- Received corticosteroids treatment or other immunodepressant within 2 weeks before the first dose of study treatment
- Toxicity from a previous anti-tumor treatment that does not return to Grade 0 or 1 (except for alopecia)
- Patients who are suffering active interstitial lung disease
- Evidence of ongoing or active serious infection
- History of human immunodeficiency virus (HIV) infection or active hepatitis B or C infection
- Inability to take medication orally
- Abuse of alcohol or drugs
- People with cognitive and psychological abnormality or with low compliance
- Pregnant or lactating women
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SEQUENTIAL
- Arm && Interventions
Group Intervention Description WX390 0.7 mg + Toripalimab 240mg WX390 Participants will receive WX390 continuous oral dosing (0.7 mg once a day) and Toripalimab fixed dose (240mg, intravenous, Day 1, every 3 weeks). WX390 0.5 mg + Toripalimab 240mg WX390 Participants will receive WX390 continuous oral dosing (0.5 mg once a day) and Toripalimab fixed dose (240mg, intravenous, Day 1, every 3 weeks). WX390 0.9 mg + Toripalimab 240mg WX390 Participants will receive WX390 continuous oral dosing (0.9 mg once a day) and Toripalimab fixed dose (240mg, intravenous, Day 1, every 3 weeks). WX390 0.5 mg + Toripalimab 240mg Toripalimab Participants will receive WX390 continuous oral dosing (0.5 mg once a day) and Toripalimab fixed dose (240mg, intravenous, Day 1, every 3 weeks). WX390 0.7 mg + Toripalimab 240mg Toripalimab Participants will receive WX390 continuous oral dosing (0.7 mg once a day) and Toripalimab fixed dose (240mg, intravenous, Day 1, every 3 weeks). WX390 0.9 mg + Toripalimab 240mg Toripalimab Participants will receive WX390 continuous oral dosing (0.9 mg once a day) and Toripalimab fixed dose (240mg, intravenous, Day 1, every 3 weeks).
- Primary Outcome Measures
Name Time Method Progression-free survival rate (PFS rate) up to 24 weeks PFS rate: is defined as the proportion of patients without objective tumor progression or death.
Maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) in DLT observation period up to 24 weeks The safety and tolerability of WX390 will be evaluated based on adverse events data. Other safety parameters include physical examination, clinical laboratory tests including coagulation function, renal function, hepatic function, blood glucose and blood lipid, etc.
Objective response rate (ORR) up to 24 weeks ORR: is defined as the proportion of patients with complete response (CR) and partial response (PR) according to RECIST 1.1.
- Secondary Outcome Measures
Name Time Method Overall survival (OS) up to 48 weeks OS: is defined as the time from randomization until death from any cause.
Disease-control rate (DCR) up to 24 weeks DCR: is defined as the proportion of patients with complete response (CR), partial response (PR) and stable disease (SD) according to RECIST 1.1.
Progression-free survival (PFS) up to 48 weeks PFS: is defined as the time from randomization until objective tumor progression or death, whichever occurs first.
Trial Locations
- Locations (1)
the first affiliated hospital of Jilin university
🇨🇳Changchun, Jilin, China